Review
Chemistry, Medicinal
Sorayya Ghasemi, Suowen Xu, Seyed Mohammad Nabavi, Mohammad Amir Amirkhani, Antoni Sureda, Silvia Tejada, Zahra Lorigooini
Summary: Epigenetic alterations play a significant role in cancer development, especially in cancer stem cells (CSCs). Epigenetic therapies targeting CSCs are emerging as a promising strategy for cancer treatment, with phenolic compounds potentially neutralizing CSCs development and metabolism through epigenetic mechanisms.
PHYTOTHERAPY RESEARCH
(2021)
Review
Pharmacology & Pharmacy
Bandana Chakravarti, Jawed Akhtar Siddiqui, Rohit Anthony Sinha, Sana Raza
Summary: Cancer stem cells (CSCs) are a subset of cancer cells that possess the ability to self-renew and initiate tumors. CSCs exhibit resistance to traditional therapies and are a major driver of disease relapse. Recent studies have revealed that CSCs have distinct metabolic properties, and metabolic reprogramming plays a crucial role in their self-renewal and maintenance.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Wanyu Li, Yanan Chen, Kun He, Tianshou Cao, Daibo Song, Huiling Yang, Li Li, Jiantao Lin
Summary: A high-efficiency mitochondrion-targeting delivery system was developed for liver cancer cells, which promoted cellular uptake of drugs and targeted mitochondria directly, leading to effective apoptosis of liver cancer cells.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Review
Oncology
Amirhossein Izadpanah, Niloufar Mohammadkhani, Mina Masoudnia, Mahsa Ghasemzad, Arefeh Saeedian, Hamid Mehdizadeh, Mansour Poorebrahim, Marzieh Ebrahimi
Summary: Accumulating data has shown that cancer stem cells (CSCs) play a crucial role in tumor metastasis and recurrence. Targeting CSC-related signaling pathways and surface markers could help eradicate tumors and improve cancer survival. Immunotherapy strategies, such as dendritic cell (DC) vaccines, chimeric antigen receptors (CAR)-engineered immune cells, and monoclonal antibodies (mAbs), have shown promising results in targeting CSCs.
Article
Pharmacology & Pharmacy
Shuang Ba, Mingxi Qiao, Li Jia, Jiulong Zhang, Xiuli Zhao, Haiyang Hu, Dawei Chen
Summary: A novel mitochondria-target derivate, when encapsulated with doxorubicin in pH-sensitive liposomes, successfully reversed chemotherapeutic resistance of cancer stem-like cells.
Review
Cell Biology
Mia C. Borlongan, Hongbin Wang
Summary: Tumorigenic cancer stem cells (CSCs) are a subset of cells within tumors that have distinct genetic and phenotypic profiles and signaling pathways compared to other tumor cells. Targeting the unique self-renewal and differentiation properties of CSCs could revolutionize cancer therapy. Understanding the signaling mechanisms of CSCs will improve our knowledge of cancer pathology and treatment.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Xin Dang, Shuwen Lei, Shuhua Luo, Yixin Hu, Juntao Wang, Dongdong Zhang, Dan Lu, Faqin Jiang, Lei Fu
Summary: The study assessed the anti-cancer activities of a novel family of TPP-thiazole derivatives, finding that these compounds exhibited significant cytotoxicity against cancer cells and effectively inhibited mitochondrial energy production.
BIOORGANIC CHEMISTRY
(2021)
Review
Cell Biology
Chiara Donini, Ramona Rotolo, Alessia Proment, Massimo Aglietta, Dario Sangiolo, Valeria Leuci
Summary: The term cancer stem cells (CSCs) refers to tumor cells with stemness features that may contribute to chemo-resistance and disease relapses, with potential susceptibility to immune system recognition and targeting. Cellular immunotherapies, including those using chimeric antigen receptors (CAR) for genetic redirection, show promise for selective elimination of CSC subsets in different tumor settings. Preclinical studies support the potential targeting of CSCs by cellular immunotherapies, with ongoing clinical studies and new opportunities for T and non-T antitumor lymphocytes.
Article
Materials Science, Biomaterials
Shengqing Zhang, Jinhong Cai, Yi Yao, Lanli Huang, Li Zheng, Jinmin Zhao
Summary: This study reports a mitochondrial-targeting nanozyme that has the potential to scavenge excessive ROS, restore mitochondrial function, and inhibit OA inflammation. In an OA joint model, this nanozyme effectively mitigated the inflammatory response.
REGENERATIVE BIOMATERIALS
(2023)
Review
Oncology
Miao Ma, Wenyou He, Keyu Zhao, Linyuan Xue, Siyuan Xia, Baotong Zhang
Summary: Prostate cancer is the most common cancer in men in the United States, and a portion of cases progress to castration-resistant and metastatic disease. Aldehyde dehydrogenase (ALDH) plays an important role in prostate cancer, with its high expression associated with higher tumor stage and lymph node metastasis. Increased ALDH activity in prostate cancer cells enhances self-renewal and metastatic capabilities, while reducing sensitivity to treatment. Targeting ALDH may hold promise for eradicating prostate cancer, but challenges remain.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Valentina Artusa, Luana Calabrone, Lorenzo Mortara, Francesco Peri, Antonino Bruno
Summary: Cancer stem cells (CSCs) are important tumour-initiating cells that play a crucial role in recurrence after chemotherapy. Targeting CSCs by exploiting their signature molecular pathways offers opportunities for therapies. Inhibiting stemness can reduce the risk posed by CSCs, limiting their capacity for tumorigenesis, proliferation, metastasis, and recurrence. This article discusses the role of CSCs in tumour biology, CSC therapy resistance mechanisms, the role of the gut microbiota in cancer development and treatment, and current advances in discovering microbiota-derived natural compounds targeting CSCs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Rajalaxmi Pradhan, Subhajit Chatterjee, Krushna Chandra Hembram, Chinmayee Sethy, Mahitosh Mandal, Chanakya Nath Kundu
Summary: Tumor associated macrophages in the tumor microenvironment secrete cytokines that regulate cancer cells growth, while Resveratrol nanoparticles reduce the properties of cancer stem like cells. By decreasing cytokine levels, Res-NP inhibits invasion, proliferation, and growth of CSCs in vitro, in vivo, and ex vivo systems.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY
(2021)
Article
Oncology
Ye Zhu, Fei Fu, Zhongyu Wang, Fen Qiu, Ting Deng, Boyu Du, Yunhe Zhu, Xueyan Xi
Summary: This study revealed the high expression of CD44 in colon cancer tissues and demonstrated CD44 as a diagnostic and predictive index for colorectal cancer. PPVII, derived from the root of Paris polyphylla, was found to inhibit the migration and sphere-forming ability of colon cancer cells, as well as downregulate the expression of CD44. These results suggest that PPVII could be a potent drug candidate for the treatment of colon cancer targeting CD44 positive cells.
CURRENT CANCER DRUG TARGETS
(2022)
Article
Chemistry, Multidisciplinary
Mankun Wei, Uli Nurjanah, Juan Li, Xinxin Luo, Rendy Hosea, Yanjun Li, Jianting Zeng, Wei Duan, Guanbin Song, Makoto Miyagishi, Vivi Kasim, Shourong Wu
Summary: Cancer stem cells (CSCs) play a crucial role in tumor progression, recurrence, and therapeutic resistance. The mechanisms underlying CSC division are poorly understood, which limits their clinical application. This study identifies Yin Yang 2 (YY2) as a negative regulator of CSC maintenance and reveals its role in suppressing liver CSC asymmetric division.
Article
Chemistry, Medicinal
Clelia Mathieu, Quentin Chamayou, Thi Thanh Hyen Luong, Delphine Naud, Florence Mahuteau-Betzer, Mouad Alami, Elias Fattal, Samir Messaoudi, Juliette Vergnaud-Gauduchon
Summary: A series of novel TRAP1 inhibitors, represented by compounds 3a-f and 5, were designed and synthesized. Among them, compound 3a exhibited excellent anti-proliferative activity in various human cancer cells. The best lead compound 6BrCaQ-C-10-TPP demonstrated potential anticancer effects by disrupting mitochondrial membrane and regulating HSP and partner protein levels.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Oncology
Vanitha N. Sivalingam, Ayse Latif, Sarah Kitson, Rhona McVey, Katherine G. Finegan, Kay Marshall, Michael P. Lisanti, Federica Sotgia, Ian J. Stratford, Emma J. Crosbie
BRITISH JOURNAL OF CANCER
(2020)
Article
Cell Biology
Bela Ozsvari, Federica Sotgia, Michael P. Lisanti
Article
Cell Biology
Camillo Sargiacomo, Federica Sotgia, Michael P. Lisanti
Article
Cell Biology
Matteo Brindisi, Marco Fiorillo, Luca Frattaruolo, Federica Sotgia, Michael P. Lisanti, Anna Rita Cappello
Article
Cell Biology
Marco Fiorillo, Fanni Toth, Matteo Brindisi, Federica Sotgia, Michael P. Lisanti
Review
Biochemistry & Molecular Biology
Francesca De Santis, Giovanni Fuca, Dirk Schadendorf, Alberto Mantovani, Luca Magnani, Michael Lisanti, Stephen Pettitt, Matteo Bellone, Giannino Del Sal, Saverio Minucci, Alexander Eggermont, Paolo Bruzzi, Silvio Bicciato, Pierfranco Conte, Roberta Noberini, John Hiscott, Filippo De Braud, Michele Del Vecchio, Massimo Di Nicola
Summary: Experts at the Tenth Edition of the Annual Congress on Anticancer Innovative Therapy shared the latest knowledge and novel therapeutic approaches in fields such as immuno-oncology, epigenetics, cancer metabolism, cancer stem cells, tumor cell signaling, and the immune system. The conference also discussed possible mechanisms of resistance to these innovative therapies, particularly with respect to immune checkpoint blockers (ICB), providing a broad overview of future challenges and hopes for improving cancer treatment in the medium-short term.
CYTOKINE & GROWTH FACTOR REVIEWS
(2021)
Article
Multidisciplinary Sciences
Cristian Scatena, Giovanni Fanelli, Giuseppe Nicolo Fanelli, Michele Menicagli, Paolo Aretini, Valerio Ortenzi, Sara Piera Civitelli, Lorenzo Innocenti, Federica Sotgia, Michael P. Lisanti, Antonio Giuseppe Naccarato
Summary: Recent evidence indicates that loss of caveolin expression in the stromal compartment of human invasive breast carcinoma may be predictive of disease recurrence, metastasis, and poor prognosis. Additionally, a study on sCav-1 expression in breast cancer and axillary lymph nodes suggests that the loss of Cav-1 in lymph nodes may contribute to metastatic spread in breast cancer.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Marco Fiorillo, Cristian Scatena, Antonio Giuseppe Naccarato, Federica Sotgia, Michael P. Lisanti
Summary: This study identifies high ATP production by the mitochondrial ATP-synthase as a new therapeutic target for anticancer therapy, particularly for inhibiting tumor progression. ATP-high cancer cells exhibit aggressive phenotypes with increased proliferation, stemness, anchorage-independence, cell migration, invasion, and multi-drug resistance, along with high antioxidant capacity. ATP depletion through targeting ATP5F1C may serve as a promising strategy for preventing metastasis and avoiding treatment failure, making ATP5F1C a potential biomarker and molecular target for future drug development to prevent metastatic disease progression.
CELL DEATH AND DIFFERENTIATION
(2021)
Article
Oncology
Camillo Sargiacomo, Sophie Stonehouse, Zahra Moftakhar, Federica Sotgia, Michael P. Lisanti
Summary: MTDR can be used to target and eradicate cancer stem cells by selectively interfering with mitochondrial metabolism in breast cancer cells. It significantly inhibits tumor growth and metastasis with little to no toxicity observed in a preclinical animal model.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Filippo Di Pisa, Elisa Pesenti, Maria Bono, Andrea N. Mazzarello, Cinzia Bernardi, Michael P. Lisanti, Giovanni Renzone, Andrea Scaloni, Ermanno Ciccone, Franco Fais, Silvia Bruno, Paolo Scartezzini, Fabio Ghiotto
Summary: This study sheds light on the potential role of SH3BGRL3 in regulating myosin-cytoskeleton interaction and cell migration. It was found that SH3BGRL3 specifically interacts with Myo1c in a Ca2+-dependent manner, suggesting a potential regulatory mechanism for cytoskeleton dynamics involving SH3BGRL3 and Myo1c.
BMC MOLECULAR AND CELL BIOLOGY
(2021)
Review
Oncology
Marco Fiorillo, Bela Ozsvari, Federica Sotgia, Michael P. Lisanti
Summary: The study suggests that high mitochondrial ATP production is a new therapeutic target for cancer treatment, isolating metabolically fit cancer cells with enhanced stem-like properties and invasive abilities. By regulating mitochondrial ATP-synthase, prevention of metastasis in cancer cells is possible.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Matteo Brindisi, Luca Frattaruolo, Marco Fiorillo, Vincenza Dolce, Federica Sotgia, Michael P. Lisanti, Anna Rita Cappello
Summary: This study found that elevated cholesterol levels increase the aggressiveness of breast cancer cells and promote the release of pro-inflammatory factors. Furthermore, there is a close symbiotic relationship between breast cancer cells and the microenvironment. These findings highlight the potential of targeting the cholesterol-ERR alpha synergy for breast cancer treatment.